COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines

被引:417
作者
Meo, S. A. [1 ]
Bukhari, I. A. [2 ]
Akram, J. [3 ]
Meo, A. S. [4 ]
Klonoff, D. C. [5 ]
机构
[1] King Saud Univ, Coll Med, Dept Physiol, Riyadh, Saudi Arabia
[2] King Saud Univ, Coll Med, Dept Pharmacol, Riyadh, Saudi Arabia
[3] Univ Hlth Sci, Dept Med, Lahore, Pakistan
[4] Natl Univ Med Sci, Army Med Coll, Rawalpindi, Pakistan
[5] Mills Peninsula Med Ctr, Diabet Res Inst, San Mateo, CA USA
关键词
SARS-CoV-2; vaccine; Pfizer/BioNTech; Moderna vaccine; Pharmacology; Adverse effects; PREVALENCE;
D O I
10.26355/eurrev_202102_24877
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: The "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" disease has caused a worldwide challenging and threatening pandemic (COVID-19), with huge health and economic losses. The US Food and Drug Administration, (FDA) has granted emergency use authorization for treatment with the Pfizer/BioNTech and Moderna COVID-19 vaccines. Many people have a history of a significant allergic reaction to a specific food, medicine, or vaccine; hence, people all over the world have great concerns about these two authorized vaccines. This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines. MATERIALS AND METHODS: The required documents and information were collected from the relevant databases, including Web of Science (Clarivate Analytics), PubMed, EMBASE, World Health Organization (WHO), Food and Drug Authorities (FDA) USA, Local Ministries, Health Institutes, and Google Scholar. The key terms used were: Coronavirus, SARS-COV-2, COVID-19 pandemic, vaccines, Pfizer/BioNTech vaccine, Moderna vaccine, pharmacology, benefits, allergic responses, indications, contraindications, and adverse effects. The descriptive information was recorded, and we eventually included 12 documents including research articles, clinical trials, and websites to record the required information. RESULTS: Based on the currently available literature, both vaccines are beneficial to provide immunity against SARS-CoV-2 infection. Pfizer/BioNTech Vaccine has been recommended to people 16 years of age and older, with a dose of 30 mu g (0.3 m) at a cost of $19.50. It provides immunogenicity for at least 119 days after the first vaccination and is 95% effective in preventing the SARS-COV-2 infection. However, Moderna Vaccine has been recommended to people 18 years of age and older, with a dose of 50 mu g (0.5 mL) at a cost of $32-37. It provides immunogenicity for at least 119 days after the first vaccination and is 94.5% effective in preventing the SARS-CoV-2 infection. However, some associated allergic symptoms have been reported for both vaccines. The COVID-19 vaccines can cause mild adverse effects after the first or second doses, including pain, redness or swelling at the site of vaccine shot, fever, fatigue, headache, muscle pain, nausea, vomiting, itching, chills, and joint pain, and can also rarely cause anaphylactic shock. The occurrence of adverse effects is reported to be lower in the Pfizer/BioNTech vaccine compared to the Moderna vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive. CONCLUSIONS: The FDA has granted emergency use authorization for the Pfizer/BioNTech and Moderna COVID-19 vaccines. These vaccines can protect recipients from a SARS-CoV-2 infection by formation of antibodies and provide immunity against a SARS-CoV-2 infection. Both vaccines can cause various adverse effects, but these reactions are reported to be less frequent in the Pfizer/BioNTech vaccine compared to the Moderna COVID-19 vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.
引用
收藏
页码:1663 / 1669
页数:7
相关论文
共 21 条
  • [1] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
    Anderson, E. J.
    Rouphael, N. G.
    Widge, A. T.
    Jackson, L. A.
    Roberts, P. C.
    Makhene, M.
    Chappell, J. D.
    Denison, M. R.
    Stevens, L. J.
    Pruijssers, A. J.
    McDermott, A. B.
    Flach, B.
    Lin, B. C.
    Doria-Rose, N. A.
    O'Dell, S.
    Schmidt, S. D.
    Corbett, K. S.
    Swanson, P. A., II
    Padilla, M.
    Neuzil, K. M.
    Bennett, H.
    Leav, B.
    Makowski, M.
    Albert, J.
    Cross, K.
    Edara, V. V.
    Floyd, K.
    Suthar, M. S.
    Martinez, D. R.
    Baric, R.
    Buchanan, W.
    Luke, C. J.
    Phadke, V. K.
    Rostad, C. A.
    Ledgerwood, J. E.
    Graham, B. S.
    Beigel, J. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) : 2427 - 2438
  • [2] The lightning-fast quest for COVID vaccines - and what it means for other diseases
    Ball, Philip
    [J]. NATURE, 2021, 589 (7840) : 16 - 18
  • [3] Center for Disease Control Prevention (CDC), INF MOD COVID 19 VAC
  • [4] Clark T., Anaphylaxis Following m-RNA COVID-19 Vaccine Receipt
  • [5] Dolgin Elie, 2020, Nat Biotechnol, DOI 10.1038/d41587-020-00022-y
  • [6] A systematic review of SARS-CoV-2 vaccine candidates
    Dong, Yetian
    Dai, Tong
    Wei, Yujun
    Zhang, Long
    Zheng, Min
    Zhou, Fangfang
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [7] An mRNA Vaccine against SARS-CoV-2-Preliminary Report
    Jackson, L. A.
    Anderson, E. J.
    Rouphael, N. G.
    Roberts, P. C.
    Makhene, M.
    Coler, R. N.
    McCullough, M. P.
    Chappell, J. D.
    Denison, M. R.
    Stevens, L. J.
    Pruijssers, A. J.
    McDermott, A.
    Flach, B.
    Doria-Rose, N. A.
    Corbett, K. S.
    Morabito, K. M.
    O'Dell, S.
    Schmidt, S. D.
    Swanson, P. A.
    Padilla, M.
    Mascola, J. R.
    Neuzil, K. M.
    Bennett, H.
    Sun, W.
    Peters, E.
    Makowski, M.
    Albert, J.
    Cross, K.
    Buchanan, W.
    Pikaart-Tautges, R.
    Ledgerwood, J. E.
    Graham, B. S.
    Beigel, J. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (20) : 1920 - 1931
  • [8] Jennings K., 2022, Forbes
  • [9] Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-03593-7
  • [10] Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379